<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11194100</article-id><article-id pub-id-type="pmcid-ver">PMC11194100.1</article-id><article-id pub-id-type="pmcaid">11194100</article-id><article-id pub-id-type="pmcaiid">11194100</article-id><article-id pub-id-type="pmid">38910701</article-id><article-id pub-id-type="doi">10.7759/cureus.61022</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Otolaryngology</subject></subj-group><subj-group><subject>Radiation Oncology</subject></subj-group><subj-group><subject>Oncology</subject></subj-group></article-categories><title-group><article-title>Comparison of Volumetric Modulated Arc Therapy (VMAT) and Conventional Intensity-Modulated Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Retrospective Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Algouneh</surname><given-names initials="A">Arash</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schneider</surname><given-names initials="K">Ken</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="K">Kitty</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hussein</surname><given-names initials="A">Abdulkadir</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pan</surname><given-names initials="M">Ming</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Radiation Oncology, Schulich School of Medicine and Dentistry, London, CAN </aff><aff id="aff-2">
<label>2</label>
Radiation Oncology, Windsor Regional Hospital Cancer Program, Windsor, CAN </aff><aff id="aff-3">
<label>3</label>
Mathematics amd Statistics, University of Windsor, Windsor, CAN </aff><author-notes><corresp id="cor1">
Arash Algouneh <email>aalgoune@uwo.ca</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>5</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>5</month><year>2024</year></pub-date><volume>16</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">461511</issue-id><elocation-id>e61022</elocation-id><history><date date-type="accepted"><day>23</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>23</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-24 17:25:31.990"><day>24</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024, Algouneh et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Algouneh et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cureus-0016-00000061022.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cureus.com/articles/252512-comparison-of-volumetric-modulated-arc-therapy-vmat-and-conventional-intensity-modulated-radiotherapy-imrt-for-locally-advanced-head-and-neck-squamous-cell-carcinoma-a-retrospective-cohort-study">This article is available from https://www.cureus.com/articles/252512-comparison-of-volumetric-modulated-arc-therapy-vmat-and-conventional-intensity-modulated-radiotherapy-imrt-for-locally-advanced-head-and-neck-squamous-cell-carcinoma-a-retrospective-cohort-study</self-uri><abstract><p>Purpose</p><p>This study examines the outcomes of locally advanced head and neck squamous cell carcinoma (HNSCC) following the adoption of conventional intensity-modulated radiotherapy (cIMRT) and volumetric-modulated arc therapy (VMAT) over a decade. The region under study has higher comorbidities associated with increased HNSCC incidence and poorer prognosis.</p><p>Materials and methods</p><p>A 10-year retrospective review of electronic medical records included 296 patients with stage III, IVA, and IVB HNSCC (American Joint Committee on Cancer, Seventh edition). Survival outcomes were compared between VMAT and cIMRT using Kaplan-Meier survival curves and adjusted for relevant demographic factors using Cox's proportional hazards model. Analysis was performed using R software&#160;(R Foundation, Vienna, Austria).</p><p>Results</p><p>The median age of the cohort was 63 years, comprising of 80% males. The oropharynx was the most common primary tumor site. 264 (89%) received 50Gy or higher dose radiation by either cIMRT (22%) or VMAT (67%). At five years, locoregional control (LC) and overall survival (OS) rates were 79.5% and 56.7%, respectively. VMAT showed a significant improvement in five-year OS (63.4% versus 43.8% for cIMRT, p=0.0023)&#160;but no significant difference in five-year LC (81% VMAT versus 74.5% cIMRT, p=0.17). Grade 3-4 acute toxicity was observed in 22% of patients.</p><p>Conclusions</p><p>VMAT and cIMRT demonstrated excellent LC in locally advanced HNSCC&#160;despite high comorbidity rates. Notably, VMAT was associated with significantly better OS compared to cIMRT. These outcomes surpass historical data, suggesting that VMAT technology may lead to improved patient outcomes. However, larger randomized controlled trials and dosimetric studies are needed to confirm these findings.</p></abstract><kwd-group kwd-group-type="author"><kwd>overall survival</kwd><kwd>locoregional control</kwd><kwd>vmat</kwd><kwd>cimrt</kwd><kwd>hpv-related hnscc</kwd><kwd>hnscc treatment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In 2022, approximately 7500 Canadians were diagnosed with head and neck cancer, and 2100 Canadians died from this disease. The most common head and neck malignancy (up to 90%) is head and neck squamous cell carcinoma (HNSCC), which develops from the mucosal epithelium in the oral cavity, pharynx, and larynx [<xref rid="REF1" ref-type="bibr">1</xref>]. Some risk factors for HNSCC include tobacco and alcohol consumption, exposure to environmental pollutants, and infection with viral agents. Specifically, persistent infection with human papillomavirus (HPV) and Epstein-Barr virus (EBV) are known etiological risk factors for HNSCC arising from the oropharynx and nasopharynx, respectively [<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF3" ref-type="bibr">3</xref>].</p><p>The diagnosis of HNSCC is established by biopsy of the primary tumor [<xref rid="REF4" ref-type="bibr">4</xref>]. Additionally, since patients with HPV-positive oropharyngeal cancer have consistently better survival than those with HPV-negative oropharyngeal cancer, HPV testing by immunohistochemistry for p16, a tumor suppressor, has become common for oropharyngeal or primary unknown cancer of the head and neck region [<xref rid="REF5" ref-type="bibr">5</xref>,<xref rid="REF6" ref-type="bibr">6</xref>]. The anatomical site of the disease, stage, functional considerations, and patient preferences determine the treatment approach.</p><p>Radiation therapy is an effective treatment for HNSCC as a primary modality, specifically in advanced HNSCC, and as an adjuvant treatment following surgery [<xref rid="REF1" ref-type="bibr">1</xref>]. However, radiation therapy is associated with acute and chronic toxicities such as mucositis, dysphagia, xerostomia, dermatitis, and pain [<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF8" ref-type="bibr">8</xref>]. Specifically, late radiation toxicity is permanent and results in reduced quality of life (QOL) for the patient, particularly xerostomia and dysphagia [<xref rid="REF9" ref-type="bibr">9</xref>]. As a result, radiation therapy for advanced HNSCC has shifted from three-dimensional conformal radiotherapy (3D-CRT) to intensity-modulated radiotherapy (IMRT). IMRT has reduced toxicities, specifically the sparing of the parotid gland, resulting in the decrease of xerostomia for patients treated with IMRT compared with 3D-CRT [<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF10" ref-type="bibr">10</xref>]. IMRT, as a definitive treatment for HNSCC, has become the standard of care in many institutions worldwide [<xref rid="REF11" ref-type="bibr">11</xref>]. Volumetric modulated arc therapy (VMAT) is a newer technique of IMRT that delivers radiation dose using a rotating gantry with varying speed and dose rate in contrast to conventional IMRT (cIMRT), which uses fixed gantry beams. Although several studies have demonstrated shorter planning and treatment time, improved dose homogeneity, and normal tissue sparing when comparing VMAT to cIMRT, few studies have explored its long-term clinical outcomes [<xref rid="REF12" ref-type="bibr">12</xref>,<xref rid="REF13" ref-type="bibr">13</xref>].</p><p>Our cancer center serves a population base of approximately 650,000. Higher smoking rates [<xref rid="REF14" ref-type="bibr">14</xref>] and alcohol consumption than the provincial average [<xref rid="REF15" ref-type="bibr">15</xref>] and the low HPV vaccination rates [<xref rid="REF16" ref-type="bibr">16</xref>] could ultimately be contributing factors to higher incidence and poorer prognosis of HNSCC in our region. We started cIMRT in 2009 and VMAT in 2012 as the standard radiation modality for the definitive treatment of locally advanced HNSCC. This study aims to review our experience with stage III, IVA, and IVB HNSCC treated with VMAT versus cIMRT by comparing outcomes and the toxicity of these two modalities over a decade.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Study approval and patient selection</p><p>This retrospective study received approval from the Windsor Regional Cancer Center's Research Ethics Board (REB) (WRH REB #21-396). We reviewed the electronic medical records (EMR) of patients presenting with head and neck malignancies over a decade. Our inclusion criteria encompassed 296 consecutive patients with locally advanced head and neck squamous cell carcinoma (HNSCC) - specifically stages III, IVA, and IVB, as classified per the American Joint Committee on Cancer, Seventh Edition (AJCC-7) guidelines [<xref rid="REF17" ref-type="bibr">17</xref>].</p><p>Data collection</p><p>We collated a comprehensive dataset for each patient, including demographics, tumor characteristics, treatment regimens, dosimetric parameters, survival outcomes, and acute and chronic toxicities.&#160;Patients were treated with various radiotherapy regimens tailored to the extent of disease and therapeutic intent. These regimens ranged from definitive radical treatments, typically administered as 70Gy over 33 to 35 fractions or 66Gy over 33 fractions, to post-operative adjuvant courses of 60Gy over 30 fractions. Palliative treatments varied in dosage, primarily 30Gy delivered over 10 fractions or 20Gy over five fractions. The therapeutic modalities evolved during the study period, beginning with conventional intensity-modulated radiation therapy (cIMRT) in August 2009 and progressing to volumetric modulated arc therapy (VMAT) in its RapidArc iteration starting in 2012. For patients in the palliative care category, three-dimensional conformal radiation therapy (3D-CRT) was predominantly utilized.</p><p>Follow-up and outcome measures</p><p>We documented recurrence patterns, distinguishing between locoregional and distant metastatic progression. Locoregional control (LC) was stringently defined to capture the absence of tumor reemergence within the initial tumor site or regional lymphatics. Overall survival (OS) was another critical endpoint, calculated from the date of treatment completion&#160;to ensure consistency with the clinical endpoint of radiation effectiveness.</p><p>Toxicity assessment</p><p>Radiation-induced toxicities were systematically categorized by severity using the established Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria [<xref rid="REF18" ref-type="bibr">18</xref>], allowing for the standardized reporting of treatment-related side effects.</p><p>Statistical analysis</p><p>A detailed subgroup analysis was conducted, from which palliative cases and early 3D-CRT treatments were excluded to focus on the comparative effectiveness of VMAT and cIMRT in a curative setting. A total of 264 patients, 198 treated with VMAT and 66 with cIMRT, were included in the model-based analysis. Survival analyses, incorporating Kaplan-Meier curves, provided unadjusted survival probabilities. Multivariate analysis using Cox's proportional hazards models enabled us to adjust for various demographic and clinical factors, potentially confounding the relationship between treatment modality and survival outcomes. All statistical computations were performed using the R statistical software (R Foundation, Vienna, Austria), ensuring rigorous and reproducible analysis.</p></sec><sec sec-type="results"><title>Results</title><p>Among all 296 patients, the median follow-up for patients still alive was 42 months (range 6-107.3 months). The median age at diagnosis was 63 years old (range 26-89), 237 (80%) patients were male, 96 (32%) had a positive P16 histology, and 156 (53%) had at least two significant comorbidities. The most common primary tumor sites were the oropharynx (51.7%), larynx (14.5%), and hypopharynx (6.4%). The breakdown of stages based on AJCC 7th edition was as follows: stage III (19.9%), IVA (74.4%), and IVB (5.6%). Furthermore, 97% of patients received radiotherapy, 89% received 50Gy or higher radiation dose, including 66 (22%) cIMRT and 198 (67%) VMAT, 30% had surgery, and 61% had chemotherapy (platinum-based or cetuximab). Baseline patient characteristics are summarized in Table <xref rid="TAB1" ref-type="table">1</xref>.</p><table-wrap position="float" id="TAB1" orientation="portrait"><label>Table 1</label><caption><title>Baseline patient demographics and clinical characteristics</title><p>cIMRT - conventional intensity-modulated radiotherapy;&#160;VMAT - volumetric-modulated arc therapy</p><p>&#160;</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Characteristic</td><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">%</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">26-96</td><td rowspan="1" colspan="1">63 (median)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">237</td><td rowspan="1" colspan="1">80%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">20%</td></tr><tr><td rowspan="1" colspan="1">Smoking history</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Smoker</td><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1">39%</td></tr><tr><td rowspan="1" colspan="1">Non-smoker or unknown history</td><td rowspan="1" colspan="1">182</td><td rowspan="1" colspan="1">61%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">P16 status available</td><td rowspan="1" colspan="1">124</td><td rowspan="1" colspan="1">42%</td></tr><tr><td rowspan="1" colspan="1">P16 positive</td><td rowspan="1" colspan="1">96</td><td rowspan="1" colspan="1">32%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Comorbidities</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">With at least 1 major comorbidity</td><td rowspan="1" colspan="1">229</td><td rowspan="1" colspan="1">77%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">With 2 or more major comorbidities</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">53%</td></tr><tr><td rowspan="1" colspan="1">Primary tumor site</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Nasopharynx</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1.00%</td></tr><tr><td rowspan="1" colspan="1">Oropharynx</td><td rowspan="1" colspan="1">153</td><td rowspan="1" colspan="1">51.70%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hypopharynx</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">6.40%</td></tr><tr><td rowspan="1" colspan="1">Larynx</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">14.50%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Nasal cavity and sinuses</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1.40%</td></tr><tr><td rowspan="1" colspan="1">Parotid</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">2.70%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Skin</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1.00%</td></tr><tr><td rowspan="1" colspan="1">Primary unknown</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">1.70%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">19.60%</td></tr><tr><td rowspan="1" colspan="1">Received EBRT</td><td rowspan="1" colspan="1">287</td><td rowspan="1" colspan="1">97%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">50Gy or higher</td><td rowspan="1" colspan="1">264</td><td rowspan="1" colspan="1">89%</td></tr><tr><td rowspan="1" colspan="1">cIMRT</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">22%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">VMAT</td><td rowspan="1" colspan="1">198</td><td rowspan="1" colspan="1">67%</td></tr><tr><td rowspan="1" colspan="1">Underwent planned surgery (primary and neck dissection)</td><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">30%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">2nd salvage surgery</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">6%</td></tr><tr><td rowspan="1" colspan="1">Received chemotherapy</td><td rowspan="1" colspan="1">182</td><td rowspan="1" colspan="1">61%</td></tr></tbody></table></table-wrap><p>Detailed analysis was performed on 264 consecutive patients who received radical doses by either VMAT or cIMRT. Marginal comparisons between the VMAT and cIMRT groups with respect to all prognostic factors are reported in Table <xref rid="TAB2" ref-type="table">2</xref>. This analysis revealed no significant difference between the two treatments in these prognostic factors except for smoking.</p><table-wrap position="float" id="TAB2" orientation="portrait"><label>Table 2</label><caption><title>Analysis of baseline patient demographic data</title><p>cIMRT - conventional intensity-modulated radiotherapy; VMAT - volumetric-modulated arc therapy; AJCC-7 - American Joint Committee on Cancer, Seventh Edition</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Covariate&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">VMAT (N= 198)</td><td rowspan="1" colspan="1">IMRT (N= 66)</td><td rowspan="1" colspan="1">Parametric p-value*</td></tr><tr><td rowspan="2" colspan="1">Gender, (N (%))</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">162 (81.82)</td><td rowspan="1" colspan="1">55 (83.33)</td><td rowspan="1" colspan="1">0.781</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Female&#160;</td><td rowspan="1" colspan="1">36 (18.18)</td><td rowspan="1" colspan="1">11 (16.67)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td colspan="2" rowspan="1">Age at diagnosis (N)</td><td rowspan="1" colspan="1">198</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">0.494</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">63.08</td><td rowspan="1" colspan="1">62.02</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Median</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">59.5</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="3" colspan="1">Stage (AJCC 7) (N (%))</td><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">40 (20.3)</td><td rowspan="1" colspan="1">12 (18.18)</td><td rowspan="1" colspan="1">0.928</td></tr><tr><td rowspan="1" colspan="1">IVA</td><td rowspan="1" colspan="1">146 (74.11)</td><td rowspan="1" colspan="1">50 (75.76)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IVB</td><td rowspan="1" colspan="1">11 (5.58)</td><td rowspan="1" colspan="1">4 (6.06)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="9" colspan="1">Sites (N (%))</td><td rowspan="1" colspan="1">Nasopharynx</td><td rowspan="1" colspan="1">3 (1.52)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0.185</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Oropharynx</td><td rowspan="1" colspan="1">110 (55.56)</td><td rowspan="1" colspan="1">33 (50)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Hypopharynx</td><td rowspan="1" colspan="1">8 (4.04)</td><td rowspan="1" colspan="1">8 (12.12)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Larynx</td><td rowspan="1" colspan="1">30 (15.15)</td><td rowspan="1" colspan="1">8 (12.12)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Nasal cavity and sinuses&#160;</td><td rowspan="1" colspan="1">2 (1.01)</td><td rowspan="1" colspan="1">1 (1.52)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Parotid</td><td rowspan="1" colspan="1">7 (3.54)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Skin</td><td rowspan="1" colspan="1">2 (1.01)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Primary unknown&#160;</td><td rowspan="1" colspan="1">4 (2.02)</td><td rowspan="1" colspan="1">1 (1.52)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Other&#160;</td><td rowspan="1" colspan="1">32 (16.16)</td><td rowspan="1" colspan="1">15 (22.73)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Smoking (N (%))</td><td rowspan="1" colspan="1">yes</td><td rowspan="1" colspan="1">60 (30.3)</td><td rowspan="1" colspan="1">40 (60.61)</td><td rowspan="1" colspan="1">&lt; .001</td></tr><tr><td rowspan="1" colspan="1">no&#160;</td><td rowspan="1" colspan="1">138 (69.7)</td><td rowspan="1" colspan="1">26 (39.39)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Comorbidities (N (%))</td><td rowspan="1" colspan="1">No comorbidities&#160;</td><td rowspan="1" colspan="1">47 (23.74)</td><td rowspan="1" colspan="1">17 (25.76)</td><td rowspan="1" colspan="1">0.136</td></tr><tr><td rowspan="1" colspan="1">Multiple</td><td rowspan="1" colspan="1">105 (53.03)</td><td rowspan="1" colspan="1">27 (40.91)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Grade 3-4 toxicities (N (%))</td><td rowspan="1" colspan="1">yes</td><td rowspan="1" colspan="1">40 (20.73)</td><td rowspan="1" colspan="1">18 (27.69)</td><td rowspan="1" colspan="1">0.245</td></tr><tr><td rowspan="1" colspan="1">no</td><td rowspan="1" colspan="1">153 (79.27)</td><td rowspan="1" colspan="1">47 (72.31)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Permanent Xerostomia (N (%))</td><td rowspan="1" colspan="1">yes</td><td rowspan="1" colspan="1">27 (15.7)</td><td rowspan="1" colspan="1">3 (4.62)</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">no</td><td rowspan="1" colspan="1">145 (84.3)</td><td rowspan="1" colspan="1">62 (95.38)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Feeding tube (N (%))</td><td rowspan="1" colspan="1">yes</td><td rowspan="1" colspan="1">47 (24.23)</td><td rowspan="1" colspan="1">22 (33.85)</td><td rowspan="1" colspan="1">0.129</td></tr><tr><td rowspan="1" colspan="1">no</td><td rowspan="1" colspan="1">147 (75.77)</td><td rowspan="1" colspan="1">43 (66.15)</td><td rowspan="1" colspan="1">&#160;</td></tr></tbody></table></table-wrap><p>There was no treatment-related death, but 22.5% of the patients had grade 3-4 acute toxicity (RTOG Acute Radiation Morbidity Scoring Criteria). There was no significant difference between the two subgroups in grade 3-4 acute toxicity and the eventual need for a feeding tube (Table <xref rid="TAB2" ref-type="table">2</xref>).</p><p>Using Kaplan-Meier Curves, the LC and OS of the entire cohort were 79.5% and 56.7% at five years, respectively (Figure <xref rid="FIG1" ref-type="fig">1</xref>). Further analysis demonstrated that treatment modality only significantly impacted five-year OS (VMAT 63.4% vs. cIMRT 43.8%, p=0.0023), but no significant difference was shown in the five-year LC (VMAT 81% vs. cIMRT 74.5%, p=0.17) (Figure <xref rid="FIG2" ref-type="fig">2</xref>).</p><fig position="anchor" fig-type="figure" id="FIG1" orientation="portrait"><label>Figure 1</label><caption><title>Overall survival (A) and local regional control (B) of the entire cohort</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0016-00000061022-i01.jpg"/></fig><fig position="anchor" fig-type="figure" id="FIG2" orientation="portrait"><label>Figure 2</label><caption><title>Overall survival (A) and local regional control (B) subdivided by treatment modality</title><p>VMAT -&#160;volumetric-modulated arc therapy; IMRT -&#160;intensity-modulated radiotherapy</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0016-00000061022-i02.jpg"/></fig><p>Cox's model showed VMAT, stage, and age at the time of diagnosis were the only factors that significantly impacted OS, with a hazard ratio (HR) of 0.583 (95% CI 0.388-0.876, VMAT vs cIMRT), HR 0.38 (95% CI 0.155-0.933, stage III vs IVB), and HR 1.526 for every 10-year increase in age (95% CI 1.269-1.836), respectively. There was no significant difference in OS between stage III vs IVA or IVA vs. IVB. Age was the only factor that significantly impacted LC, with HR 1.4 (95% CI 1.046-1.874) for every 10 years increase in age (Tables <xref rid="TAB3" ref-type="table">3</xref> and 4).</p><table-wrap position="float" id="TAB3" orientation="portrait"><label>Table 3</label><caption><title>Hazard ratios for overall survival </title><p>VMAT -&#160;volumetric-modulated arc therapy; IMRT -&#160;intensity-modulated radiotherapy</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Factors</td><td rowspan="1" colspan="1">HR</td><td colspan="2" rowspan="1">95% confidence limits</td></tr><tr><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">&#160;</td><td colspan="2" rowspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">VMAT vs. IMRT</td><td rowspan="1" colspan="1">0.583</td><td rowspan="1" colspan="1">0.388</td><td rowspan="1" colspan="1">0.876</td></tr><tr><td rowspan="1" colspan="1">Stage</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">III vs. IVA</td><td rowspan="1" colspan="1">0.636</td><td rowspan="1" colspan="1">0.371</td><td rowspan="1" colspan="1">1.091</td></tr><tr><td rowspan="1" colspan="1">III vs. IVB</td><td rowspan="1" colspan="1">0.380</td><td rowspan="1" colspan="1">0.155</td><td rowspan="1" colspan="1">0.933</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IVA vs. IVB</td><td rowspan="1" colspan="1">0.597</td><td rowspan="1" colspan="1">0.274</td><td rowspan="1" colspan="1">1.301</td></tr><tr><td rowspan="1" colspan="1">Age at diagnosis</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">10 years older</td><td rowspan="1" colspan="1">1.526</td><td rowspan="1" colspan="1">1.269</td><td rowspan="1" colspan="1">1.836</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB4" orientation="portrait"><label>Table 4</label><caption><title>Hazard ratios for local control</title><p>VMAT -&#160;volumetric-modulated arc therapy; IMRT -&#160;intensity-modulated radiotherapy</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Factors</td><td rowspan="1" colspan="1">HR</td><td colspan="2" rowspan="1">95% confidence limits</td></tr><tr><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">&#160;</td><td colspan="2" rowspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">VMAT vs. IMRT</td><td rowspan="1" colspan="1">0.581</td><td rowspan="1" colspan="1">0.306</td><td rowspan="1" colspan="1">1.104</td></tr><tr><td rowspan="1" colspan="1">Stages</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">III vs. IVA</td><td rowspan="1" colspan="1">5.377</td><td rowspan="1" colspan="1">0.892</td><td rowspan="1" colspan="1">32.421</td></tr><tr><td rowspan="1" colspan="1">III vs. IVB</td><td rowspan="1" colspan="1">1.198</td><td rowspan="1" colspan="1">0.364</td><td rowspan="1" colspan="1">3.946</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IVA vs. IVB</td><td rowspan="1" colspan="1">0.223</td><td rowspan="1" colspan="1">0.053</td><td rowspan="1" colspan="1">0.941</td></tr><tr><td rowspan="1" colspan="1">Age at diagnosis</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">10 years older</td><td rowspan="1" colspan="1">1.400</td><td rowspan="1" colspan="1">1.046</td><td rowspan="1" colspan="1">1.874</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>In the last decade, IMRT has become more common in treating HNSCC. Several studies have demonstrated that IMRT has reduced toxicities, such as the decreased incidence of xerostomia post-radiation, compared to older technologies [<xref rid="REF10" ref-type="bibr">10</xref>,<xref rid="REF19" ref-type="bibr">19</xref>]. Radiation oncologists are able to prescribe a higher dose safely without worrying about severe toxicity to critical organs such as the spinal cord, which was difficult to achieve using 3D-CRT. VMAT, a newer technique of IMRT, has demonstrated reduced treatment planning and delivery time with improved dose homogeneity. It is a fast, safe, and accurate technique that uses lower monitor units (MU) by nearly 60% than cIMRT [<xref rid="REF12" ref-type="bibr">12</xref>]. Still, few studies have directly compared the long-term clinical outcomes of VMAT to cIMRT.</p><p>Our present study is one of the first to evaluate the outcome of VMAT versus cIMRT for treating locally advanced HNSCC (stage III-IVB) between 2009 and 2019. Several previous studies have reported on the role of cIMRT and VMAT for specific HNSCC sites, such as the oropharynx, or explored these modalities for all stages of HNSCC. However, to date, few studies have focused on locally advanced HNSCC, which are associated with poorer outcomes. Nevertheless, in our analysis, the three-year LC and OS were 80% and 70%, and the five-year LC and OS were 79.5% and 56.7%, respectively, which is consistent with the values reported in the literature for IMRT treatment of locally advanced HNSCC [<xref rid="REF20" ref-type="bibr">20</xref>-<xref rid="REF23" ref-type="bibr">23</xref>].</p><p>In our study, treatment modality only significantly impacted five-year OS (VMAT 63.4% vs. cIMRT 43.8%, p=0. 0003), but not the five-year LC (VMAT 81% vs. cIMRT 74.5%, p=0.21) (Figure <xref rid="FIG2" ref-type="fig">2</xref>). Interestingly, Smet&#160;et al. also compared 78 cases of cIMRT and 79 cases of VMAT in locally advanced HNSCC, with almost all patients having stage III-IV disease, and found no significant differences in three-year OS (70.8 vs. 57.3%, p=0.219) or LC (84.9 vs. 72.7%, p=0.118) between the two groups [<xref rid="REF20" ref-type="bibr">20</xref>]. This discrepancy in OS could be attributed to their equal (and also smaller) number of patients in the cIMRT and VMAT groups compared to our study, where 75% of the patients were treated with VMAT [<xref rid="REF20" ref-type="bibr">20</xref>]. We have a long median follow-up of 42 months, making the five-year LC and OS analysis available. It is possible that the OS difference would become significant with longer follow-ups, as in our study. However, in the Smet&#160;et al. study, 80% of patients also received concurrent chemotherapy, as opposed to only 61% in our study (due to significant comorbidities), which could account for the observed differences.&#160;</p><p>Limitations of the study</p><p>Considering the limitation of our study due to its retrospective nature, caution should be taken. The cIMRT subgroup was treated between 2009 and 2012, while the VMAT subgroup was treated between 2012 and 2019. There is selection bias due to the availability of more advanced radiation technology in recent years. Additionally, during this period, immunotherapeutic agents have improved recurrent and metastatic HNSCC patients' OS after treatment failure of standard dose concurrent chemoradiation [<xref rid="REF24" ref-type="bibr">24</xref>]. Although none of our patients received salvage immunotherapy during the study period, improved supportive care might have contributed to better survival in recent years. It is also possible that the p16-positive oropharyngeal cancer patients were not equally distributed in the two subgroups, as we did not have routine p16 tests in the early years. Our institution started to use AJCC-8 staging after March 2019. It is impractical to convert all the staging of our cohort to this new version that considers p16 status as a very important prognostic factor, i.e., it has not been possible to obtain cell blocks to reassess these cases since 2009. P16-positive patients are known to have better OS compared&#160;to the p16-negative and cigarette smoking-related HNSCC.</p><p>Nonetheless, the difference in OS between VMAT and cIMRT with no difference in LC is unexpected. This is unusual, given that any form of radiotherapy is a local treatment. However, earlier studies did confirm that improved LC by treating early-stage breast cancer patients with postoperative radiation did translate into a survival benefit in the long term, even when systemic therapy was given [<xref rid="REF25" ref-type="bibr">25</xref>]. Proportional gains might be larger because of more effective radiotherapy for breast cancer, which might be similar to HNSCC.</p><p>Additionally, there were no significant differences in acute or late toxicities between treatment modalities in our study (except for xerostomia), which could have indicated that the OS difference might be from the impact of the patient's other comorbidities. One such factor that could explain this anomaly is the significantly higher smoking rate in the cIMRT vs. VMAT cohort, 60.6% vs. 30.3%, thus, more likely to develop more future comorbidities associated with smoking and impact the OS. Due to the retrospective nature of our study, this could not have been circumvented.</p><p>Alternatively, this could be a statistical anomaly that other more extensive studies failed to show.&#160;Unfortunately, it is not practical to design a phase III multicenter randomized controlled trial to compare VMAT and cIMRT due to the obvious advantage of VMAT, such as patient comfort thanks to quicker delivery time (on average, three minutes for VMAT versus 10-15 minutes for cIMRT). Randomizing any patients into the cIMRT arm would be unethical should such a trial be planned in the future. A retrospective cohort study might be the only and best way to compare these two treatment modalities to locally advanced HNSCC.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Our study presents evidence of VMAT's efficacy over cIMRT in enhancing overall survival for patients with locally advanced HNSCC. The results suggest that VMAT may improve long-term survival outcomes. Additionally, we identify a complex relationship between treatment modalities, patient characteristics, and treatment outcomes, emphasizing the importance of individualized treatment planning. The limitations of retrospective analyses, such as potential selection bias and evolving treatment protocols, were acknowledged. Nonetheless, the observed trend towards improved survival with VMAT supports its consideration in future clinical decision-making. This work contributes to the growing evidence for refining radiation therapy techniques and underscores the need for prospective research to enhance treatment efficacy against head and neck cancer.</p></sec></body><back><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#160; Arash Algouneh, Ming Pan</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#160; Arash Algouneh, Ken Schneider, Kitty Huang, Abdulkadir Hussein, Ming Pan</p><p><bold>Drafting of the manuscript:</bold>&#160; Arash Algouneh, Ming Pan</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#160; Arash Algouneh, Ken Schneider, Kitty Huang, Abdulkadir Hussein, Ming Pan</p><p><bold>Supervision:</bold>&#160; Ming Pan</p></fn></fn-group><fn-group content-type="other"><title>Human Ethics</title><fn fn-type="other"><p>Consent was obtained or waived by all participants in this study. Windsor Regional Cancer Center Research Ethics Board issued approval #21-396</p></fn></fn-group><fn-group content-type="other"><title>Animal Ethics</title><fn fn-type="other"><p><bold>Animal subjects:</bold> All authors have confirmed that this study did not involve animal subjects or tissue.</p></fn></fn-group><notes><fn-group content-type="competing-interests"><fn fn-type="COI-statement"><p>The authors have declared financial relationships, which are detailed in the next section.</p></fn><fn fn-type="financial-disclosure"><p>Arash Algouneh declare(s) a grant from CARO-CROF Dr. Pamela Catton 2021 Summer Studentship Award.</p></fn></fn-group></notes><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Head and neck squamous cell carcinoma</article-title><source>Nat Rev Dis Primers</source><person-group><name name-style="western"><surname>Johnson</surname><given-names>DE</given-names></name><name name-style="western"><surname>Burtness</surname><given-names>B</given-names></name><name name-style="western"><surname>Leemans</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lui</surname><given-names>VW</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Grandis</surname><given-names>JR</given-names></name></person-group><fpage>92</fpage><volume>6</volume><year>2020</year><pub-id pub-id-type="pmid">33243986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-020-00224-3</pub-id><pub-id pub-id-type="pmcid">PMC7944998</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Translational genomics of nasopharyngeal cancer</article-title><source>Semin Cancer Biol</source><person-group><name name-style="western"><surname>Tsang</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lui</surname><given-names>VW</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>JP</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Lo</surname><given-names>KW</given-names></name></person-group><fpage>84</fpage><lpage>100</lpage><volume>61</volume><year>2020</year><pub-id pub-id-type="pmid">31521748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2019.09.006</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications</article-title><source>J Dent Res</source><person-group><name name-style="western"><surname>Hennessey</surname><given-names>PT</given-names></name><name name-style="western"><surname>Westra</surname><given-names>WH</given-names></name><name name-style="western"><surname>Califano</surname><given-names>JA</given-names></name></person-group><fpage>300</fpage><lpage>306</lpage><volume>88</volume><year>2009</year><pub-id pub-id-type="pmid">19407148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0022034509333371</pub-id><pub-id pub-id-type="pmcid">PMC3317947</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Clinical practice guideline: Evaluation of the neck mass in adults</article-title><source>Otolaryngol Head Neck Surg</source><person-group><name name-style="western"><surname>Pynnonen</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>MB</given-names></name><name name-style="western"><surname>Roman</surname><given-names>B</given-names></name><etal/></person-group><fpage>0</fpage><volume>157</volume><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0194599817722550</pub-id><pub-id pub-id-type="pmid">28891406</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: an updated systematic review and meta-analysis of 30 trials</article-title><source>Head Neck</source><person-group><name name-style="western"><surname>Petrelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Sarti</surname><given-names>E</given-names></name><name name-style="western"><surname>Barni</surname><given-names>S</given-names></name></person-group><fpage>750</fpage><lpage>759</lpage><volume>36</volume><year>2014</year><pub-id pub-id-type="pmid">23606404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.23351</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation</article-title><source>CMAJ</source><person-group><name name-style="western"><surname>Habbous</surname><given-names>S</given-names></name><name name-style="western"><surname>Chu</surname><given-names>KP</given-names></name><name name-style="western"><surname>Lau</surname><given-names>H</given-names></name><etal/></person-group><fpage>0</fpage><lpage>40</lpage><volume>189</volume><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.161379</pub-id><pub-id pub-id-type="pmcid">PMC5555753</pub-id><pub-id pub-id-type="pmid">28808115</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors</article-title><source>Head Neck</source><person-group><name name-style="western"><surname>Wijers</surname><given-names>OB</given-names></name><name name-style="western"><surname>Levendag</surname><given-names>PC</given-names></name><name name-style="western"><surname>Braaksma</surname><given-names>MM</given-names></name><name name-style="western"><surname>Boonzaaijer</surname><given-names>M</given-names></name><name name-style="western"><surname>Visch</surname><given-names>LL</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>PI</given-names></name></person-group><fpage>737</fpage><lpage>747</lpage><volume>24</volume><year>2002</year><pub-id pub-id-type="pmid">12203798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.10129</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer</article-title><source>Otolaryngol Head Neck Surg</source><person-group><name name-style="western"><surname>Kelly</surname><given-names>C</given-names></name><name name-style="western"><surname>Paleri</surname><given-names>V</given-names></name><name name-style="western"><surname>Downs</surname><given-names>C</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R</given-names></name></person-group><fpage>108</fpage><lpage>111</lpage><volume>136</volume><year>2007</year><pub-id pub-id-type="pmid">17210344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.otohns.2006.06.1278</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms</article-title><source>Br J Cancer</source><person-group><name name-style="western"><surname>Hammerlid</surname><given-names>E</given-names></name><name name-style="western"><surname>Taft</surname><given-names>C</given-names></name></person-group><fpage>149</fpage><lpage>156</lpage><volume>84</volume><year>2001</year><pub-id pub-id-type="pmid">11161369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1054/bjoc.2000.1576</pub-id><pub-id pub-id-type="pmcid">PMC2363699</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><person-group><name name-style="western"><surname>Braam</surname><given-names>PM</given-names></name><name name-style="western"><surname>Terhaard</surname><given-names>CH</given-names></name><name name-style="western"><surname>Roesink</surname><given-names>JM</given-names></name><name name-style="western"><surname>Raaijmakers</surname><given-names>CP</given-names></name></person-group><fpage>975</fpage><lpage>980</lpage><volume>66</volume><year>2006</year><pub-id pub-id-type="pmid">16965864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2006.06.045</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Head and neck cancer: improving outcomes with a multidisciplinary approach</article-title><source>Cancer Manag Res</source><person-group><name name-style="western"><surname>Lo Nigro</surname><given-names>C</given-names></name><name name-style="western"><surname>Denaro</surname><given-names>N</given-names></name><name name-style="western"><surname>Merlotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Merlano</surname><given-names>M</given-names></name></person-group><fpage>363</fpage><lpage>371</lpage><volume>9</volume><year>2017</year><pub-id pub-id-type="pmid">28860859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CMAR.S115761</pub-id><pub-id pub-id-type="pmcid">PMC5571817</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study</article-title><source>Int J Radiat Oncol Biol Phys</source><person-group><name name-style="western"><surname>Verbakel</surname><given-names>WF</given-names></name><name name-style="western"><surname>Cuijpers</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hoffmans</surname><given-names>D</given-names></name><name name-style="western"><surname>Bieker</surname><given-names>M</given-names></name><name name-style="western"><surname>Slotman</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Senan</surname><given-names>S</given-names></name></person-group><fpage>252</fpage><lpage>259</lpage><volume>74</volume><year>2009</year><pub-id pub-id-type="pmid">19362244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2008.12.033</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT</article-title><source>Radiother Oncol</source><person-group><name name-style="western"><surname>Vanetti</surname><given-names>E</given-names></name><name name-style="western"><surname>Clivio</surname><given-names>A</given-names></name><name name-style="western"><surname>Nicolini</surname><given-names>G</given-names></name><etal/></person-group><fpage>111</fpage><lpage>117</lpage><volume>92</volume><year>2009</year><pub-id pub-id-type="pmid">19157609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.radonc.2008.12.008</pub-id></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="webpage"><article-title>Ontario Agency for Health Protection and Promotion (Public Health Ontario)</article-title><year>2018</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.publichealthontario.ca/-/media/documents/T/2019/tobacco-report-2018.pdf">https://www.publichealthontario.ca/-/media/documents/T/2019/tobacco-report-2018.pdf</uri></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Self-reported alcohol use snapshot - historical</article-title><fpage>2013</fpage><lpage>2014</lpage><volume>2003</volume><year>2014</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.publichealthontario.ca/en/Data-and-Analysis/Substance-Use/Alcohol-Use/Alcohol-Use-Historical">https://www.publichealthontario.ca/en/Data-and-Analysis/Substance-Use/Alcohol-Use/Alcohol-Use-Historical</uri></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="webpage"><article-title>Background and key statistics on HPV immunization in Canada</article-title><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.partnershipagainstcancer.ca/topics/hpv-immunization-policies/background-key-statistics">https://www.partnershipagainstcancer.ca/topics/hpv-immunization-policies/background-key-statistics</uri></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM</article-title><source>Ann Surg Oncol</source><person-group><name name-style="western"><surname>Edge</surname><given-names>SB</given-names></name><name name-style="western"><surname>Compton</surname><given-names>CC</given-names></name></person-group><fpage>1471</fpage><lpage>1474</lpage><volume>17</volume><year>2010</year><pub-id pub-id-type="pmid">20180029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-010-0985-4</pub-id></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy</article-title><source>Int J Radiat Oncol</source><person-group><name name-style="western"><surname>Trotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Byhardt</surname><given-names>R</given-names></name><name name-style="western"><surname>Stetz</surname><given-names>J</given-names></name><etal/></person-group><fpage>13</fpage><lpage>47</lpage><volume>47</volume><year>2000</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0360-3016(99)00559-3</pub-id><pub-id pub-id-type="pmid">10758303</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer</article-title><source>World J Surg</source><person-group><name name-style="western"><surname>Eisbruch</surname><given-names>A</given-names></name><name name-style="western"><surname>Ship</surname><given-names>JA</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>LA</given-names></name><etal/></person-group><fpage>832</fpage><lpage>837</lpage><volume>27</volume><year>2003</year><pub-id pub-id-type="pmid">14509515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00268-003-7105-6</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>Clinical and dosimetric evaluation of RapidArc versus standard sliding window IMRT in the treatment of head and neck cancer</article-title><source>Strahlenther Onkol</source><person-group><name name-style="western"><surname>Smet</surname><given-names>S</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>M</given-names></name><name name-style="western"><surname>Vanstraelen</surname><given-names>B</given-names></name><name name-style="western"><surname>Nuyts</surname><given-names>S</given-names></name></person-group><fpage>43</fpage><lpage>50</lpage><volume>191</volume><year>2015</year><pub-id pub-id-type="pmid">25168752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00066-014-0742-x</pub-id></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers</article-title><source>Br J Radiol</source><person-group><name name-style="western"><surname>Bhide</surname><given-names>SA</given-names></name><name name-style="western"><surname>Newbold</surname><given-names>KL</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Nutting</surname><given-names>CM</given-names></name></person-group><fpage>487</fpage><lpage>494</lpage><volume>85</volume><year>2012</year><pub-id pub-id-type="pmid">22556403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1259/bjr/85942136</pub-id><pub-id pub-id-type="pmcid">PMC3479880</pub-id></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Recurrence patterns after IMRT/VMAT in head and neck cancer</article-title><source>Front Oncol</source><person-group><name name-style="western"><surname>Bollen</surname><given-names>H</given-names></name><name name-style="western"><surname>van der Veen</surname><given-names>J</given-names></name><name name-style="western"><surname>Laenen</surname><given-names>A</given-names></name><name name-style="western"><surname>Nuyts</surname><given-names>S</given-names></name></person-group><fpage>720052</fpage><volume>11</volume><year>2021</year><pub-id pub-id-type="pmid">34604056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.720052</pub-id><pub-id pub-id-type="pmcid">PMC8483718</pub-id></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Treatment: Outcome and toxicity of volumetric modulated arc therapy in oropharyngeal carcinoma</article-title><source>Anticancer Res</source><person-group><name name-style="western"><surname>Franzese</surname><given-names>C</given-names></name><name name-style="western"><surname>Fogliata</surname><given-names>A</given-names></name><name name-style="western"><surname>Franceschini</surname><given-names>D</given-names></name><etal/></person-group><fpage>3451</fpage><lpage>3457</lpage><volume>36</volume><year>2016</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/27354607">https://pubmed.ncbi.nlm.nih.gov/27354607</uri><pub-id pub-id-type="pmid">27354607</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study</article-title><source>Lancet</source><person-group><name name-style="western"><surname>Burtness</surname><given-names>B</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Greil</surname><given-names>R</given-names></name><etal/></person-group><fpage>1915</fpage><lpage>1928</lpage><volume>394</volume><year>2019</year><pub-id pub-id-type="pmid">31679945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32591-7</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials</article-title><source>Lancet</source><person-group><name name-style="western"><surname>McGale</surname><given-names>P</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>C</given-names></name><name name-style="western"><surname>Correa</surname><given-names>C</given-names></name><etal/></person-group><fpage>2127</fpage><lpage>2135</lpage><volume>383</volume><year>2014</year><pub-id pub-id-type="pmid">24656685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(14)60488-8</pub-id><pub-id pub-id-type="pmcid">PMC5015598</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>